D

DANGOND F.

Last name: DANGOND F.

2021 (v1)

Publication

Metadata-only

Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal

Dangond F. Donnelly A. Hohlfeld R.

Therapies for infiltrative inflammation in multiple sclerosis (MS) have advanced greatly, but neurodegeneration and compartmentalized inflammation remain virtually untargeted as in other diseases of the nervous system. Consequently, many therapies are available for the relapsing–remitting form of MS, but the progressive forms remain essentially...

Uploaded on: April 14, 2023
2022 (v1)

Publication

Metadata-only

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

De Stefano N. Sormani M. P. Giovannoni G.

Background: In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study of patients with relapsing-remitting multiple sclerosis, treatment with cladribine tablets 3.5 mg/kg (CladT) significantly reduced the annualised relapse rate (ARR) versus placebo; this effect was sustained in CLARITY Extension, without further treatment....

Uploaded on: April 14, 2023